Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Parkinson Disease Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.
Parkinson Disease Market Overview
The global parkinson disease market is on the brink of significant growth, with projections indicating a potential reach of $8.8 billion by the year 2030. This growth, characterized by a robust CAGR of 6.1% from 2024 to 2030, is spurred by a constellation of factors, including an increasing aging populace, technological advancements in diagnostics, and surging healthcare expenditures in emerging economies.
Segmentation Analysis and Regional Outlook
A detailed segmentation analysis reveals that the market is expanding across various drug classes such as carbidopa-levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and anticholinergics. Distribution channels also play a key role, with hospital pharmacy, retail pharmacy, and online pharmacy comprising the primary categories. Geographically, North America retains the crown as the largest region in the parkinson disease market, attributed to its array of market participants, high income levels, elevated healthcare costs, and well-established healthcare infrastructure.
Competitive Landscape and Market Dynamics
The competitive landscape remains dynamic, with key players employing strategies such as manufacturing expansion, research and development investments, and integration across the value chain. These maneuvers aim at meeting the growing demand, sustaining competitiveness, fostering innovation, curtailing production costs, and broadening customer bases. The market's upward trajectory is not without its challenges and business risks, which include competitive threats and material or product substitution. Nonetheless, emerging trends and customer demands continue to shape market developments, with major players at the helm ushering in a new era of treatments that are poised to significantly improve patient outcomes.
Growth Opportunities and Strategic Analysis
Forecasts suggest that the retail pharmacy segment will witness substantial growth, maintaining its leading position over the forecast period due to its accessibility to patients. As the market for parkinson disease treatments evolves, strategic initiatives including mergers and acquisitions have left indelible marks on the industry, influencing market structures and strategies. The parkinson disease market's future is replete with growth opportunities across diverse drug classes and distribution channels, setting the stage for an era of robust development and innovation in the treatment of this pervasive disease.
A selection of companies mentioned in this report includes, but is not limited to:
- Cerevel Therapeutics
- Novartis
- Teva Pharmaceutical Industries
- Merck & Co.
- GlaxoSmithKline
- AbbVie
- H. Lundbeck
For more information about this report visit https://www.researchandmarkets.com/r/t17vdo
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
